RPRX today
$68.97-$1.04 (-1.49%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourLeaning Bearish
1 hourBearish
15 minLeaning Bullish
5 minConsolidating
Daily trend turns down below $55.13
Key levels
Support$67.70
Support$64.84
Latest news & SEC filings
SEC FilingRoyalty Pharma plc filed an insider trading report (Form 4)
AnalystCitigroup keeps Buy rating on Royalty Pharma, lifts target to $78
All RPRX news →About Royalty Pharma
Royalty Pharma buys rights to receive a share of sales from biopharmaceutical products. Its holdings cover marketed medicines for conditions such as rare disease, cancer, immune disorders, neurological conditions, blood disorders, lung disease and diabetes, plus some therapies still being tested. The company provides funding to universities, hospitals, charities, smaller drug developers and large drugmakers, and it works globally.
Based on the company's 10-K filed Feb 11, 2026.
Nasdaq · Healthcare
Royalty Pharma plc (RPRX)
What Is the Price Target for RPRX?
SEPT Low Target
$62.00
SEPT Mid Target
$67.50
SEPT High Target
$78.00
Analyst Consensus
$67.50
Is RPRX a Buy or Sell Right Now?
Thesis
- •Revenue growing 5.1% YoY with SLOWING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RPRX.
Start Free Trial →Is RPRX Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, Analyst Consensus
Fair Value
$73.66
28
Moat Score
NONE
5/9
Piotroski Score
2.9
Altman Z-Score
What Is Smart Money Doing with RPRX?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Urist Marshall | officer | Buy | 150,000 | - | Nov 6, 2026 |
| Coyne Terrance P. | officer | Buy | 150,000 | - | Nov 6, 2026 |
| Coyne Terrance P. | officer | Buy | 100,000 | - | Nov 6, 2026 |
| Legorreta Pablo G. | director officer | Buy | 42,209 | - | Nov 4, 2026 |
| Urist Marshall | officer | Buy | 5,341 | - | Nov 4, 2026 |
| Coyne Terrance P. | officer | Buy | 7,122 | - | Nov 4, 2026 |
| Hite Christopher | officer | Buy | 7,122 | - | Nov 4, 2026 |
| Urist Marshall | officer | Sale | 4,126 | $236K | Oct 5, 2026 |
| Bassler Bonnie L | director | Buy | 642 | $37K | Sep 30, 2026 |
| Urist Marshall | officer | Sale | 4,126 | $239K | Sep 28, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RPRX Growth Story
Revenue YoY
5.1%
3yr Revenue CAGR
2.1%
EPS Growth YoY
-6.81%
FCF Growth YoY
N/A%
Revenue Trend
SLOWING
Dark Pool Trades for RPRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RPRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:27 | $68.97 | 2,417 | $$167K | BUY |
| 21:00:27 | $68.97 | 2,424 | $$167K | BUY |
| 21:00:25 | $68.97 | 4,446 | $$307K | BUY |
| 21:00:21 | $68.97 | 18,722 | $$1.3M | BUY |
| 21:00:07 | $68.97 | 58,796 | $$4.1M | BUY |
5 dark pool trades shown · $$6.0M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for RPRX
PREVIEWSEPT Investing provides real-time options flow tracking for RPRX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $75 | Jan 15 | 64 | $$500 | 5 | SWEEP |
| CALL | $75 | Jan 15 | 64 | $$400 | 4 | SWEEP |
| CALL | $75 | Jan 15 | 64 | $$100 | 1 | SWEEP |
| CALL | $75 | Jan 15 | 64 | $$500 | 5 | SWEEP |
4 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About RPRX
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for RPRX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $RPRX -- Neutral RPRX at $52.95. Day range $51.15-$54.38. Price testing zone top $53.29. Demand zone (98% institutional buying). Break above = buyers still pushing. Above $53.29, next z...
Join 3,500+ traders discussing RPRX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Royalty Pharma plc (RPRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RPRX — frequently asked questions
What is RPRX stock price today?
Royalty Pharma plc (RPRX) is at $68.97, down 1.49% (-$1.04) at the Nov 12, 2026 close.
Why is RPRX stock moving today?
Latest RPRX news — Nov 6, 2026: Royalty Pharma plc filed an insider trading report (Form 4) · Nov 5, 2026: Citigroup keeps Buy rating on Royalty Pharma, lifts target to $78
Why did RPRX stock move on Nov 4, 2026?
Royalty Pharma shares rose 2.91% to close at $67.56 after the company reported Q3 2026 adjusted earnings of $1.21 per share, beating the $1.18 consensus estimate, and raised its full-year 2026 outlook. However, revenue of $690.000 million came in well below the $796.528 million consensus, a bearish signal that may cap further upside.
What is the RPRX price target?
The average analyst price target for RPRX is $67.50, ranging from $62 to $78, based on 4 analysts. Latest: Citigroup maintains on Nov 5, 2026.
What do analysts rate RPRX?
Analyst ratings for RPRX: 0 Buy, 7 Hold, 0 Sell — consensus Hold.
Did RPRX beat earnings?
RPRX last reported on Nov 4, 2026: EPS $1.21 vs $1.18 expected — a beat of 2.5%.
Does RPRX pay a dividend?
Yes. RPRX's dividend yield is 2.27%.
How much debt does RPRX have?
Royalty Pharma plc reported $8.6B of debt and $514M of cash (Sep 30, 2026).
What are RPRX support and resistance levels?
Support: $67.70, $64.84, $62.45.
What are insiders doing with RPRX?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on RPRX?
Nov 6, 2026: Royalty Pharma plc filed an insider trading report (Form 4) · Nov 5, 2026: Citigroup keeps Buy rating on Royalty Pharma, lifts target to $78